BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Impax Pharmaceuticals 

30831 Huntwood Avenue

Hayward  California  94544  U.S.A.
Phone: 510-476-2000 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






 Company News
Impax Pharmaceuticals (IPXL) Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting 3/19/2013 9:42:47 AM    More...
Impax Pharmaceuticals (IPXL) Fails to Win Approval for Parkinson's Drug 1/22/2013 7:47:01 AM    More...
Impax Pharmaceuticals (IPXL): FDA Extends Review on Rytary NDA 10/12/2012 7:33:10 AM    More...
Impax Pharmaceuticals Release: Data from ASCEND-PD Phase III Study of IPX066 to be Presented at the American Academy of Neurology Conference 4/18/2012 9:57:16 AM    More...
FDA Accepts Impax Pharmaceuticals NDA Filing for IPX066 for the Treatment of Idiopathic Parkinson’s Disease 2/23/2012 6:16:33 AM    More...
Impax Pharmaceuticals Gains Rights for US Sales of AstraZeneca PLC (AZN)'s Zomig; Paying $130 Million in 2012 2/1/2012 7:19:51 AM    More...
Impax Pharmaceuticals Submits New Drug Application for IPX066 in Parkinson’s Disease 12/21/2011 1:47:53 PM    More...
Impax Pharmaceuticals Initiates Phase IIb Trial of IPX159 in Restless Legs Syndrome 12/19/2011 9:39:35 AM    More...
Impax Pharmaceuticals Completes Enrollment in ASCEND-PD Phase III Trial of IPX066 in Parkinson’s Disease 7/26/2011 7:07:15 AM    More...
Impax Pharmaceuticals Awarded Michael J. Fox Foundation Grant for Ongoing Research of IPX066 for Parkinson’s Disease 7/14/2011 9:06:40 AM    More...
12

//-->